Muscarinic cholinergic signaling and overactive bladder‑like symptoms associated with invasive bladder cancer

Wei,Wei; Wang,Minggang; Li,Yunglong; Meng,Qinggui; Tang,Yong; Lu,Haoyuan; Yu,Wenchao; Cheng,Qiwei; Li,You; Xu,Long; Jian,Shaojun; Wu,Yuexian; Yi,Xianlin; Xie,Keji

doi:10.3892/ol.2018.8715

Muscarinic cholinergic signaling and overactive bladder‑like symptoms associated with invasive bladder cancer

Authors:
- Wei Wei
- Minggang Wang
- Yunglong Li
- Qinggui Meng
- Yong Tang
- Haoyuan Lu
- Wenchao Yu
- Qiwei Cheng
- You Li
- Long Xu
- Shaojun Jian
- Yuexian Wu
- Xianlin Yi
- Keji Xie
View Affiliations

Affiliations: Department of Radiology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Department of Urology, Affiliated Hospital of Qinghai University, Xining, Qinghai 810016, P.R. China, Department of Urology, First People's Hospital of Kunshan, Kunshan, Jiangsu 215300, P.R. China, Department of Urology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Hubei Engineering Laboratory for Synthetic Microbiology, Wuhan Institute of Biotechnology, Wuhan, Hubei 430075, P.R. China, Department of Urology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China, Department of Respiratory, Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: May 16, 2018 https://doi.org/10.3892/ol.2018.8715
Pages: 775-784
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The objective of the present study was to explore the association between muscarinic cholinergic signaling and urothelial bladder tumors. Possible associations among overactive bladder (OAB) symptoms and bladder tumors were retrospectively investigated using a multicenter Chinese database with prospectively collected data since 2010. Firstly, it was demonstrated that OAB symptoms, such as urgency, were more severe in patients with invasive bladder cancer and were associated with a reduced prognosis. Following this, muscarinic cholinergic receptor 3 (M3R) expression in urothelium was determined to be lower in invasive cancer tissue than in adjacent non‑cancerous tissue, yet M3R upregulation was associated with a reduced progression free survival (PFS) time. Additionally, it was also demonstrated that muscarinic cholinergic receptor 2 (M2R) was upregulated in the sub‑urothelium, and this was also associated with a reduced PFS time. Furthermore, it was determined that cholinesterase and acetylcholinesterase were lower in invasive cancer than in non‑invasive cancer. In conclusion, the results indicated that M3R expression was downregulated in invasive bladder cancer, which may have a role as a protective anti‑oncogene, in contrast to its oncogenic role in numerous other cancer types. Therefore, muscarinic cholinergic signaling may be a novel therapeutic target for treating bladder cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A and Witjes JA: The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 55:815–825. 2009. View Article : Google Scholar : PubMed/NCBI
3	Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A and Palou-Redorta J: European Association of Urology (EAU): EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 54:303–314. 2008. View Article : Google Scholar : PubMed/NCBI
4	Kao LT, Huang CY, Lin HC and Chu CM: No increased risk of fracture in patients receiving antimuscarinics for overactive bladder syndrome: A retrospective cohort study. J Clin Pharmacol. Jan 9–2018.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
5	Balachandran AA and Duckett J: Metastatic breast cancer presenting as detrusor overactivity. BMJ Case Rep. 2014:pii: bcr2014207920. 2014. View Article : Google Scholar : PubMed/NCBI
6	Haferkamp A, Schurch B, Reitz A, Krengel U, Grosse J, Kramer G, Schumacher S, Bastian PJ, Büttner R, Müller SC and Stöhrer M: Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol. 46:784–791. 2004. View Article : Google Scholar : PubMed/NCBI
7	Ito Y, Kashiwabara M, Yoshida A, Hikiyama E, Onoue S and Yamada S: Muscarinic receptor binding in rat bladder urothelium and detrusor muscle by intravesical solifenacin. Biol Pharm Bull. 39:1167–1171. 2016. View Article : Google Scholar : PubMed/NCBI
8	Hawthorn MH, Chapple CR, Cock M and Chess-Williams R: Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol. 129:416–419. 2000. View Article : Google Scholar : PubMed/NCBI
9	Wang CT, Chen TM, Mei CT, Chang CF, Liu LL, Chiu KH, Wu TM, Lan YC, Liu WS and Chen YH: The Functional Haplotypes of CHRM3 Modulate mRNA Expression and Associate with Bladder Cancer among a Chinese Han Population in Kaohsiung City. Biomed Res Int. 2016:40528462016. View Article : Google Scholar : PubMed/NCBI
10	Sun Y and Chai T: 319 the role of m3 muscarinic signaling in bladder urothelial cancer cell proliferation and apoptosis. J Urol. 183:2010. View Article : Google Scholar
11	Gutkind JS, Novotny EA, Brann MR and Robbins KC: Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes. Proc Natl Acad Sci USA. 88:4703–4707. 1991. View Article : Google Scholar : PubMed/NCBI
12	Ashkenazi A, Ramachandran J and Capon DJ: Acetylcholine analogue stimulates DNA synthesis in brain-derived cells via specific muscarinic receptor subtypes. Nature. 340:146–150. 1989. View Article : Google Scholar : PubMed/NCBI
13	Von Rosenvinge EC and Raufman JP: Muscarinic receptor signaling in colon cancer. Cancers (Basel). 3:971–981. 2011. View Article : Google Scholar : PubMed/NCBI
14	Parnell EA, Calleja-Macias IE, Kalantari M, Grando SA and Bernard HU: Muscarinic cholinergic signaling in cervical cancer cells affects cell motility via ERK1/2 signaling. Life Sci. 91:1093–1098. 2012. View Article : Google Scholar : PubMed/NCBI
15	Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, Yamanishi T, Yamaguchi O, Takeda M and Nishizawa O: Symptom assessment tool for overactive bladder syndrome-overactive bladder symptom score. Urology. 68:318–323. 2006. View Article : Google Scholar : PubMed/NCBI
16	Yi X: Expression and clinical significance of M1-5 receptor subtype of bladder mucosa in patients with OAB [D]. Guang Zhou South Med Univ. 2011.
17	Humphrey PA, Moch H, Cubilla AL, Ulbright TM and Reuter VE: The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: Prostate and bladder tumours. Eur Urol. 70:106–119. 2016. View Article : Google Scholar : PubMed/NCBI
18	Tully BT, Li M, Sun Y, Berkowitz J and Chai TC: Defects in muscarinic receptor cell signaling in bladder urothelial cancer cell lines. Urology. 74:467–473. 2009. View Article : Google Scholar : PubMed/NCBI
19	Pacini L, De Falco E, Di Bari M, Coccia A, Siciliano C, Ponti D, Pastore AL, Petrozza V, Carbone A, Tata AM and Calogero A: M2muscarinic receptors inhibit cell proliferation and migration in urothelial bladder cancer cells. Cancer Biol Ther. 15:1489–1498. 2014. View Article : Google Scholar : PubMed/NCBI
20	Bschleipfer T, Schukowski K, Weidner W, Grando S, Schwantes U, Kummer W and Lips K: Expression and distribution of cholinergic receptors in the human urothelium. Life Sci. 80:2303–2307. 2007. View Article : Google Scholar : PubMed/NCBI
21	Yamanishi T, Kaga K, Fuse M, Shibata C, Kamai T and Uchiyama T: The role of muscarinic receptor subtypes on carbachol-induced contraction of normal human detrusor and overactive detrusor associated with benign prostatic hyperplasia. J Pharmacol Sci. 128:65–70. 2015. View Article : Google Scholar : PubMed/NCBI
22	Park YS and Cho NJ: Enhanced proliferation of SNU-407 human colon cancer cells by muscarinic acetylcholine receptors. BMB Rep. 41:803–807. 2008. View Article : Google Scholar : PubMed/NCBI
23	Feng YJ, Zhang BY, Yao RY and Lu Y: Muscarinic acetylcholine receptor M3 in proliferation and perineural invasion of cholangiocarcinoma cells. Hepatobiliary Pancreat Dis Int. 11:418–423. 2012. View Article : Google Scholar : PubMed/NCBI
24	Arrighi N, Bodei S, Lucente A, Michel MC, Zani D, Simeone C, Cunico SC, Spano PF and Sigala S: Muscarinic receptors stimulate cell proliferation in the human urothelium-derived cell line UROtsa. Pharmacol Res. 64:420–425. 2011. View Article : Google Scholar : PubMed/NCBI
25	Arrighi N, Bodei S, Zani D, Michel MC, Simeone C, Cunico Cosciani S, Spano P and Sigala S: Different muscarinic receptor subtypes modulate proliferation of primary human detrusor smooth muscle cells via Akt/PI3K and map kinases. Pharmacol Res. 74:1–6. 2013. View Article : Google Scholar : PubMed/NCBI
26	Campoy FJ, Vidal CJ, Muñoz-Delgado E, Montenegro MF, Cabezas-Herrera J and Nieto-Cerón S: Cholinergic system and cell proliferation. Chem Biol Interact. 259:257–265. 2016. View Article : Google Scholar : PubMed/NCBI
27	Spindel ER: Muscarinic receptor agonists and antagonists: Effects on cancer. Handb Exp Pharmacol. 208:451–468. 2012. View Article : Google Scholar
28	Peng Z, Heath J, Drachenberg C, Raufman JP and Xie G: Cholinergic muscarinic receptor activation augments murine intestinal epithelial cell proliferation and tumorigenesis. BMC Cancer. 13:2042013. View Article : Google Scholar : PubMed/NCBI
29	Liu WT, Huang KY, Lu MC, Huang HL, Chen CY, Cheng YL, Yu HC, Liu SQ, Lai NS and Huang HB: TGF-β upregulates the translation of USP15 via the PI3K/AKT pathway to promote p53 stability. Oncogene. 36:2715–2723. 2017. View Article : Google Scholar : PubMed/NCBI